What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Participants will receive one dose of 25 mg of oral psilocybin on the first dosing day and a second dose of 25mg oral psilocybin on the second dosing day. TRP 8802 will be administered in a comfortable setting under the guidance of the same two therapists from the preparation period. Participants will have an in-person study visit following the resolution of the psychoactive effects of the…”In the company’s words, NCT06206265 on ClinicalTrials.gov
- Tested for
- Irritable Bowel Syndrome
- Main trialPhase 2
- “Participants with IBS (all subtypes) and with no exclusionary comorbid psychiatric or medical disorders will be enrolled in the study. This study will involve a randomized waitlist control design to investigate the rapid and sustained effects of TRP-8802 following two experimental sessions in which an oral dose of TRP-8802 is administered to participants with IBS. The study will include clinician and participant ratings of depression and anxiety pre- and post-drug-session, monitor and participant ratings of subjective drug effects during and after each drug session. This study comprises…”In the company’s words, NCT06206265 on ClinicalTrials.gov
- Other names
- Psilocybin
Other drugs for Irritable Bowel Syndrome
- EluxadolineAbbVie · Phase 3
- Saccharomyces boulardii CNCM I-745Biocodex · Phase 3
- CamlipixantBellus Health Inc. - a GSK company · Phase 2
- BrenipatideEli Lilly · Phase 2
- TrimedatValenta Pharm JSC · Phase 1
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials5
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Active, not recruiting | 1 Mar 2026 | Assessment of Psilocybin (TRP-8802) in Concert With Psychotherapy in Patients With Irritable Bowel Syndrome (IBS) | |
| Phase 2Completed | 7 Mar 2024 | Evaluation of Psilocybin (TRP-8802) in the Treatment of Binge Eating Disorder | |
| Phase 2Authorised | not given | The impact of psilocybin on pain in fibromyalgia patients: a multicenter trial | |
| Phase 2Authorised | not given | Regression of Atherosclerosis induced by liFe chAnging Experience with psiLocybin | |
| Phase 2Authorised | not given | Psilocybin in treatment-resistant depression |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026